Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Common Equity (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Common Equity for 7 consecutive years, with $9.5 million as the latest value for Q3 2025.

  • For Q3 2025, Common Equity rose 16.35% year-over-year to $9.5 million; the TTM value through Sep 2025 reached $9.5 million, up 16.35%, while the annual FY2024 figure was $8.8 million, 21.6% down from the prior year.
  • Common Equity hit $9.5 million in Q3 2025 for Cyclerion Therapeutics, up from $8.6 million in the prior quarter.
  • Across five years, Common Equity topped out at $65.2 million in Q2 2021 and bottomed at $3.9 million in Q1 2023.
  • Average Common Equity over 5 years is $21.2 million, with a median of $10.5 million recorded in 2022.
  • Year-over-year, Common Equity plummeted 89.4% in 2023 and then skyrocketed 152.82% in 2024.
  • Cyclerion Therapeutics' Common Equity stood at $48.2 million in 2021, then crashed by 78.34% to $10.5 million in 2022, then grew by 8.0% to $11.3 million in 2023, then decreased by 21.6% to $8.8 million in 2024, then increased by 7.77% to $9.5 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $9.5 million, $8.6 million, and $8.8 million for Q3 2025, Q2 2025, and Q1 2025 respectively.